Literature DB >> 20516206

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.

Cristina Romei1, Stefano Mariotti, Laura Fugazzola, Augusto Taccaliti, Furio Pacini, Giuseppe Opocher, Caterina Mian, Maurizio Castellano, Ettore degli Uberti, Isabella Ceccherini, Nadia Cremonini, Ettore Seregni, Fabio Orlandi, Piero Ferolla, Efisio Puxeddu, Francesco Giorgino, Annamaria Colao, Paola Loli, Fabio Bondi, Barbara Cosci, Valeria Bottici, Antonello Cappai, Giovanni Pinna, Luca Persani, Uberta Verga, Verga Uberta, Marco Boscaro, Maria Grazia Castagna, Carlo Cappelli, Maria Chiara Zatelli, Antongiulio Faggiano, Giuseppe Francia, Maria Luisa Brandi, Alberto Falchetti, Aldo Pinchera, Rossella Elisei.   

Abstract

OBJECTIVE: Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disease characterized by medullary thyroid carcinoma (MTC) associated (MEN 2A and 2B) or not familial MTC (FMTC) with other endocrine neoplasia due to germline RET gene mutations. The prevalence of these rare genetic diseases and their corresponding RET mutations are unknown due to the small size of the study population.
METHODS: We collected data on germline RET mutations of 250 families with hereditary MTC followed in 20 different Italian centres. RESULTS AND
CONCLUSIONS: The most frequent RET amino acid substitution was Val804Met (19.6%) followed by Cys634Arg (13.6%). A total of 40 different germline RET mutations were present. Six families (2.4%) were negative for germline RET mutations. The comparison of the prevalence of RET germline mutations in the present study with those published by other European studies showed a higher prevalence of Val804Met and Ser891Ala mutations and a lower prevalence of Leu790Phe and Tyr791Phe (P<0.0001). A statistically significant higher prevalence of mutations affecting non-cysteine codons was also found (P<0.0001). Furthermore, the phenotype data collection showed an unexpected higher prevalence of FMTC (57.6%) with respect to other MEN 2 syndromes (34% MEN 2A and 6.8% of MEN 2B). In conclusion, we observed a statistically significant different pattern of RET mutations in Italian MEN 2 families with respect to other European studies and a higher prevalence of FMTC phenotype. The different ethnic origins of the patients and the particular attention given to analysing apparently sporadic MTC for RET germline mutations may explain these findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516206     DOI: 10.1530/EJE-10-0333

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  43 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

2.  Clinical utility gene card for: multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Susanne Rondot; Egbert Schulze; Sylwia Szpak-Ulczok; Barbara Jarzab; Karin Frank-Raue
Journal:  Eur J Hum Genet       Date:  2011-08-24       Impact factor: 4.246

Review 3.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

Review 4.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

5.  Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.

Authors:  Dana T Yip; Maria Hassan; Kalliopi Pazaitou-Panayiotou; Daniel T Ruan; Atul A Gawande; Randall D Gaz; Francis D Moore; Richard A Hodin; Antonia E Stephen; Peter M Sadow; Gilbert H Daniels; Gregory W Randolph; Sareh Parangi; Carrie C Lubitz
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

6.  Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.

Authors:  Brittany Bohinc; Gregory Michelotti; Anna Mae Diehl
Journal:  Thyroid       Date:  2013-09       Impact factor: 6.568

7.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

Review 8.  Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Authors:  Ying-Hsia Chu; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 9.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

10.  In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Authors:  Frauke Bentzien; Marcus Zuzow; Nathan Heald; Anna Gibson; Yongchang Shi; Leanne Goon; Peiwen Yu; Stefan Engst; Wentao Zhang; Donghui Huang; Lora Zhao; Valentina Vysotskaia; Felix Chu; Rajana Bautista; Belinda Cancilla; Peter Lamb; Alison H Joly; F Michael Yakes
Journal:  Thyroid       Date:  2013-09-17       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.